An Observational Study of RoActemra/Actemra in Patients With Moderate to Severe Rheumatoid Arthritis

Multicenter REtrospective Study to Evaluate coMpliance to Therapy and Drug survIval of Tocilizumab (TCZ) in patientS With Moderate to Severe actIve rheumatOid Arthritis in routiNe Daily Clinical Practice (REMISSION Study)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01375478

Enrollment

197

Registered

2011-06-17

Start date

2011-04-30

Completion date

2012-04-30

Last updated

2016-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Brief summary

This open-label, retrospective, observational study will evaluate the compliance to RoActemra/Actemra (tocilizumab) therapy in patients with moderate to severe rheumatoid arthritis. Six months data will be collected from patients records.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult patients, over 18 years of age * Moderate to severe rheumatoid arthritis * RoActemra/Actemra treatment must have been initiated 6 months prior to signing the informed consent form

Exclusion criteria

* Patients with rheumatic autoimmune disease other than rheumatoid arthritis * Patients who are not willing to sign the informed consent form * Patients who participate in interventional trials during the period of this observational study

Design outcomes

Primary

Measure	Time frame
Percentage of patients who remained under continued RoActemra/Actemra treatment	6 months

Secondary

Measure	Time frame
Reasons for withdrawal	6 months
Frequency of withdrawal	6 months
Frequency of dose modification	6 months
Reasons for dose modification	6 months
Safety: Incidence of adverse events	6 months

Countries

Greece

Outcome results